

3-20-2023

## **An Interesting Case of Disseminated Histoplasmosis in a Patient With Hemophagocytic Lymphohistiocytosis**

Rachel Ann Pellegrino

Roopa Naik

Atul Bali

# An Interesting Case of Disseminated Histoplasmosis in a Patient With Hemophagocytic Lymphohistiocytosis

Review began 03/01/2023  
Review ended 03/16/2023  
Published 03/20/2023

© Copyright 2023  
Pellegrino et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Rachel Ann Pellegrino <sup>1</sup>, Roopa Naik <sup>2, 3</sup>, Atul Bali <sup>4, 5, 2</sup>

1. Internal Medicine, Kansas City University, Danville, USA 2. Medicine, Geisinger Commonwealth School of Medicine, Scranton, USA 3. Internal Medicine/Hospital Medicine, Geisinger Health System, Wilkes-Barre, USA 4. Internal Medicine/Nephrology, Geisinger Medical Center, Danville, USA 5. Internal Medicine/Nephrology, Geisinger Health System, Wilkes-Barre, USA

Corresponding author: Roopa Naik, dr.roopanaik@gmail.com

---

## Abstract

Histoplasmosis is a common mycosis in North and Central America caused by *Histoplasma capsulatum*. Affected patients typically remain asymptomatic. However, in some individuals, histoplasmosis can present as a severe illness, usually occurring in patients with underlying risk factors such as the immunocompromised (e.g., acquired immunodeficiency syndrome (AIDS), treatment with immunosuppressive agents), and the elderly without underlying immunocompromised conditions. Here, we present a case of disseminated histoplasmosis diagnosed as an incidental finding on bone marrow biopsy while treating a hospitalized patient for hemophagocytic lymphohistiocytosis. The patient presented with weight loss, anorexia, fatigue, and generalized weakness. The patient was successfully treated with amphotericin B and eventually transitioned to itraconazole.

---

**Categories:** Internal Medicine, Allergy/Immunology, Infectious Disease

**Keywords:** opportunistic fungal infection, complication of rheumatoid arthritis, rheumatoid arthritis, ra, infectious disease pathology, histoplasmosis in bone marrow

## Introduction

*Histoplasma capsulatum* is a dimorphic fungus typically asymptomatic in immunocompetent hosts [1]. Endemic to Midwestern states in the Ohio and Mississippi River valleys, histoplasmosis can be found worldwide but predominantly in North and Central America [2]. The infection is transmitted by the inhalation of spores in soils that have been contaminated by bat or bird droppings [1]. Although severe illness caused by *Histoplasma capsulatum* is rare, disseminated infections in immunocompromised hosts, such as those with acquired immunodeficiency syndrome (AIDS) or of extremes of age, have been reported in the literature [2]. Here, we report a case of disseminated histoplasmosis incidentally found in a patient with a history of rheumatoid arthritis who presented with weight loss and weakness, diagnosed with hemophagocytic lymphohistiocytosis during the same hospitalization.

## Case Presentation

A 63-year-old Caucasian female with a history of rheumatoid arthritis (RA) and depression presented to our hospital for two months of cough, lethargy, weakness, and weight loss. She had lost about 50 pounds over the past year, but her condition had deteriorated rapidly in the preceding two months. She was on weekly methotrexate and twice daily hydroxychloroquine before her presentation. On a prior routine visit with her primary care physician preceding her weight loss, no overt concerning findings were noted. On presentation, she had a fever of 102.8°F, a heart rate of 117 beats per minute, and a respiratory rate of 28 per minute. Her body mass index (BMI) at admission was 13.79 (BMI 18.5 - 24.9). Initial laboratory assessments are listed in Table 1.


### How to cite this article

Pellegrino R, Naik R, Bali A (March 20, 2023) An Interesting Case of Disseminated Histoplasmosis in a Patient With Hemophagocytic Lymphohistiocytosis. Cureus 15(3): e36404. DOI 10.7759/cureus.36404

Laboratory parameters	Lab values	Reference values
White blood cell count	5.06/ $\mu$ L	4.00–11.00/ $\mu$ L
Hemoglobin	8.2 g/dL	12.0-15.0 g/dL
Platelet count	85,000/ $\mu$ L	140,000–400,000/ $\mu$ L
Aspartate transaminase	43 IU/L	15–37 IU/L
Alanine transaminase	20 IU/L	0–56 IU/L
Total bilirubin	0.7 mg/dL	0.2–1.3 mg/dL
Serum creatinine	1.20 mg/dL	0.6–1.3 mg/dL
Phosphorus	1.7 mg/dL	2.8 to 4.5 mg/dL
Potassium	3.4 mmol/L	3.6 to 5.2 mmol/L
Magnesium	1.3 mh/dL	1.7 to 2.2 mg/dL
Lactate dehydrogenase	479 U/L	125-243 U/L
Ferritin	5928 ng/mL	8-252 ng/mL
International normalized ratio (INR)	1.8	1.0-2.0
Iron	29 ug/dL	40-145 ug/dL
Fibrinogen	37 mg/dL	200-400 mg/dL
Iron	29 ug/dL	40-145 ug/dL
Total iron-binding capacity	275 ug/dL	250-450 ug/dL
Urinalysis		
White blood cell count	17/high power field	0–3/high power field
Red blood cell count	1 / high power field	0–3/high power field
Leukocyte esterase	Small	Absent
Nitrites	Negative	Absent
Bacteria	Many	Absent

**TABLE 1: Laboratory values on the day of admission**

Computed tomography (CT) of the chest showed no evidence of nodules, infiltrates, or any other abnormality. In contrast, CT of the abdomen and pelvis showed a non-distended gallbladder with likely surrounding fluid without any other abnormalities and was negative for lymphadenopathy or hepatosplenomegaly. Due to bacteriuria in the context of fever, a provisional diagnosis of urinary tract infection was made, and the patient was started on intravenous ceftriaxone. Subsequently, urine cultures grew pan-sensitive *Escherichia coli*, while blood cultures showed no growth. The viral hepatitis panel and human immunodeficiency virus (HIV) panel were negative. Hematology was consulted for the evaluation of pancytopenia. Peripheral smear showed normocytic anemia, neutrophilia with left shift, absolute lymphopenia, and moderate thrombocytopenia. Over the next few days, the patient received several units of packed red blood cells, platelets, and fresh frozen plasma due to worsening pancytopenia. She also developed painful ulcerations involving her lips and tongue and was started on an acyclovir suspension for possible herpes simplex infection. Bone marrow biopsy revealed hemophagocytosis, hypercellular marrow (60-70%) with erythroid hyperplasia and dyspoiesis, increased bone marrow storage of iron, and the unexpected finding of numerous small, small, narrow-based budding yeast cells noted intracellularly within macrophages (Figure 1).



**FIGURE 1: Bone marrow histopathology images with Histoplasma and hemophagocytosis**

*Histoplasma* (A-C) and hemophagocytosis (C-F) in the patient's marrow smears (Wright Giemsa, 1000x oil immersion). Numerous small, narrow-base budding yeast cells within macrophages (red arrows in A-C). Hemophagocytes with ingested granulocytes (green arrow in D-F).

A diagnosis of hemophagocytic lymphohistiocytosis (HLH) was made, with the concomitant finding of disseminated histoplasmosis (DH). HLH diagnosis criteria are enlisted in Table 2 [3].

#### Hemophagocytic lymphohistiocytosis diagnostic criteria

Fever  $\geq 38.5^{\circ}\text{C}$

Splenomegaly

Peripheral blood cytopenia

Plus at least 2 of the following

Hemoglobin  $< 9$  g/dL (for infants  $< 4$  weeks, hemoglobin  $< 10$  g/dL)

Platelets  $< 100,000/\text{microL}$

Hypertriglyceridemia (fasting triglycerides  $> 265$  mg/dL)

Absolute neutrophil count  $< 1000/\text{microL}$

Hypofibrinogenemia (fibrinogen  $< 150$  mg/dL)

Hemophagocytosis in bone marrow, spleen, lymph node, or liver

Low or absent nature killer (NK) cell activity

Ferritin  $> 500$  ng/mL

Elevated soluble CD25 (soluble IL-2 receptor alpha (sIL-2R))

**TABLE 2: Hemophagocytic lymphohistiocytosis diagnosis criteria**

Five of the above criteria are needed to establish the diagnosis of hemophagocytic lymphohistiocytosis.

Due to the risks associated with a delay in diagnosis, some experts deem a modified criterion sufficient to diagnose HLH: three of four clinical findings (fever, splenomegaly, cytopenias, hepatitis) plus abnormality of one of four immune markers (hemophagocytosis, increased ferritin, hypofibrinogenemia, absent or very decreased nature killer (NK) cell function) [3]. Since our patient presented with fever, had low fibrinogen, elevated ferritin, with evidence of hemophagocytosis, cytopenias, and transient hepatitis, this constellation

of findings led to the diagnosis of HLH in our patient. Her preceding pulmonary symptoms and weight loss, mucocutaneous ulcerations, with a subsequent note of *Histoplasma capsulatum* (H. capsulatum) on bone marrow biopsy, suggested DH was the likely etiology of this subacute presentation. The differential diagnosis for this patient is broad, including infectious, noninfectious, and cardiac causes [4-15].

The patient was started on high-dose intravenous dexamethasone. As the patient responded well and the cell counts improved on steroid therapy, etoposide was held and was not used. Since the diagnosis of DH was made, antibacterial agents were stopped in favor of starting intravenous amphotericin B, followed by the addition of oral itraconazole to her regimen. Given her baseline characteristics suggesting chronic susceptibility to infections (due to rheumatoid arthritis and the need for immunosuppressive therapy), maintenance of long-term itraconazole was recommended. While the patient had a prolonged hospital course, complicated by renal manifestations of amphotericin B and subsequent development of refeeding syndrome, overall, her clinical course improved with a slow but reassuring response to treatment.

Ultimately, she was discharged to a skilled nursing facility with outpatient follow-up with an infectious disease specialist, hematologist, and primary care physician. An outpatient monitoring plan was devised to evaluate her response to itraconazole by periodically monitoring her urine and serum for *Histoplasma* and *Blastomyces* antigens and monthly lab assessments of her hematological and metabolic parameters.

## Discussion

*Histoplasma capsulatum* is a fungus that grows as a mold in the environment. Once the spores are inhaled into the lungs, they transform into their yeast form, which can also occur in environments over 37°C. Akin to tuberculosis, the neutrophils, macrophages, lymphocytes, and natural killer cells respond to fight the infection. Macrophages also have an inherent fungicidal capacity. Most human hosts who inhale the spores remain asymptomatic. However, the disease can disseminate in those with macrophage activation deficiencies [16]. Similarly, individuals receiving immunosuppressive medications that alter their immune response are susceptible. On bone marrow biopsy, this can be seen as macrophages containing 2-to-4-micron yeast structures [17].

Disseminated histoplasmosis typically presents in individuals as pulmonary histoplasmosis [2]. Data from two large urban outbreaks in Indianapolis suggested that immunosuppression, older age, and coexisting chronic illnesses were the primary risk factors for acquiring disseminated histoplasmosis [18]. It is well-known that an immunocompromised state and old age predispose to disseminated infections [19,20]. Of the 66 cases of disseminated histoplasmosis reviewed in the above study, two-thirds of patients reported some combination of central nervous system findings, splenomegaly, hepatomegaly, and lymphopenia [18].

Mucosal lesions have been noted in the literature in HIV-infected patients with disseminated histoplasmosis [21], even though the differential diagnosis of mucosal lesions in HIV patients can be broad [22]. A study in Brazil of 36 HIV-infected patients reported that 33 had mucocutaneous histoplasmosis (oral papules, crusted papules, and oro-mucosal erosions) as a manifestation of disseminated disease [18]. However, this is not commonly reported in individuals without HIV. HLH is a syndrome of excessive inflammation and tissue destruction typically caused by excessive immune activation [17]. Seen predominantly in infants from birth to 18 months of age, it has less commonly been noted in older adults. Both infection and genetic predispositions may contribute to disease etiology, but its pathophysiology is poorly understood. Preexisting autoimmune and rheumatologic diseases in adults are reported in cases of HLH in the literature [23-27]. It can also be associated with malignancies like Hodgkin lymphoma [28].

There is limited literature on the superimposition of HLH on disseminated histoplasmosis. However, the treatment for patients acutely ill with HLH is chemotherapy and immunotherapy, followed by bone marrow transplant in relapsing or recurrent disease [29]. Conversely, chemotherapy and immunotherapy can lead to immunosuppression, predisposing to opportunistic infections with organisms such as *Histoplasma capsulatum*.

The appropriate treatment of severely ill patients with disseminated histoplasmosis requiring hospitalization is a lipid formulation of amphotericin B followed by oral itraconazole for maintenance therapy [30]. These patients typically respond well to amphotericin B if they can tolerate the side effects and stop taking the formulation after one to two weeks of treatment [30]. Itraconazole is utilized for maintenance therapy for at least a year or as long as the patient remains immunosuppressed, which may be for a lifetime for most patients with disseminated histoplasmosis [31]. Patients with mild to moderate disseminated disease are treated solely with itraconazole [30]. A study found that amphotericin B was effective for severe cases of disseminated histoplasmosis when a cumulative dose of at least 500 mg was administered [18].

## Conclusions

There are several unique features in our reported case. As mentioned, our patient had a history of rheumatoid arthritis, a predisposing factor to disseminated histoplasmosis. One of her presenting symptoms was a mucocutaneous manifestation, which has only previously been noted in HIV-infected patients. Our

patient's unique presentation and concurrent diagnosis of HLH have not been cited in the literature, thus resulting in a complicated approach to treatment. Mortality rates of HLH in immunosuppressed adults are high when prompt treatment is not instituted, as is the case with disseminated histoplasmosis. Our patient had underlying RA, which might have led to an immunocompromised state, resulting in infection with *Histoplasma capsulatum* with subsequent dissemination. It is plausible that the macrophage activation in response to *Histoplasma* infection and its subsequent dissemination led to a surge in cytokine release that, in our susceptible patient, served as the trigger for HLH. To our knowledge, this is the first reported case in the literature of a patient with disseminated histoplasmosis and associated HLH, and thus sharing this unique case would help enhance our understanding of both of these elusive disease processes.

## Additional Information

### Disclosures

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

### References

1. Evrard S, Caprasse P, Gavage P, et al.: Disseminated histoplasmosis: case report and review of the literature. *Acta Clin Belg*. 2018, 73:556-63. [10.1080/17843286.2017.1376454](https://doi.org/10.1080/17843286.2017.1376454)
2. Azar MM, Hage CA: Clinical perspectives in the diagnosis and management of histoplasmosis. *Clin Chest Med*. 2017, 38:403-15. [10.1016/j.ccm.2017.04.004](https://doi.org/10.1016/j.ccm.2017.04.004)
3. Filipovich AH: Hemophagocytic lymphohistiocytosis (HLH) and related disorders. *Hematology Am Soc Hematol Educ Program*. 2009, 2009:127-31. [10.1182/asheducation-2009.1.127](https://doi.org/10.1182/asheducation-2009.1.127)
4. Singh A, Zafar Y, & Makovec A: 2589 Disseminated Salmonella species-induced septic shock: a case report. *Am J Gastroenterol*. 2019, 114:S1424. [10.14309/01.ajg.0000599888.59552.e](https://doi.org/10.14309/01.ajg.0000599888.59552.e)
5. Jakhar I, Singh M, Singh A, Sahil S, Singh D: Risk factors for the development of severe gastrointestinal dysmotility in patients with systemic sclerosis. *J Immunol*. 2022, 208:158. [10.4049/jimmunol.208.Supp.158.16](https://doi.org/10.4049/jimmunol.208.Supp.158.16)
6. Jakhar I, Singh M, Sahil S, Singh A, Singh D: Bowel disease (IBD). *Gastroenterology*. 162:S21-2. [10.1053/j.gastro.2021.12.048](https://doi.org/10.1053/j.gastro.2021.12.048)
7. Singh A, Patel K, Patel F, Saxon JT, Grodzinsky A: An overlooked cause of myocardial infarction with normal coronaries presenting as stress cardiomyopathy in females. *Cureus*. 2023, 15:e33251. [10.7759/cureus.33251](https://doi.org/10.7759/cureus.33251)
8. Singh A, Singh D: Treadmill exercise stress test-induced takotsubo cardiomyopathy: a case report and review of literature. *Cureus*. 2023, 15:e33426. [10.7759/cureus.33426](https://doi.org/10.7759/cureus.33426)
9. Qarajeh R, Singh A, Khariton Y, Rafie N, Baweja P: Recurrent ST elevation myocardial infarction from norepinephrine-induced coronary vasospasm. *Cureus*. 2020, 12:e7605. [10.7759/cureus.7605](https://doi.org/10.7759/cureus.7605)
10. Patel KK, Singh A, Bateman TM: The potential of F-18 Flurpiridaz PET/CT myocardial perfusion imaging for precision imaging. *Curr Cardiol Rep*. 2022, 24:987-94. [10.1007/s11886-022-01713-5](https://doi.org/10.1007/s11886-022-01713-5)
11. Lehenbauer K, Qarajeh R, Shatla I, et al.: Multimodality imaging: coronary calcium scoring and myocardial blood flow reserve to predict underlying multivessel coronary artery disease. *J Cardiovasc Comput Tomogr*. 2020, 14:S64. [10.1016/j.jcct.2020.06.121](https://doi.org/10.1016/j.jcct.2020.06.121)
12. Patel K, Singh A, Peri-Okonny P, et al.: Importance of ischemia among asymptomatic patients with diabetes mellitus undergoing positron emission tomography (PET) myocardial perfusion imaging. *J Am Coll Cardiol*. 2020, 1016:0735-1097. [10.1016/S0735-1097\(20\)32426-8](https://doi.org/10.1016/S0735-1097(20)32426-8)
13. Singh A, Hardin BI, Singh D, et al.: Epidemiologic and Etiologic Considerations of Obesity. *StatPearls [Internet]*, Treasure Island (FL); 2022.
14. Cignarella A, Mioni R, Sabbadin C, et al.: Pharmacological approaches to controlling cardiometabolic risk in women with PCOS. *Int J Mol Sci*. 2020, 21:9554. [10.3390/ijms21249554](https://doi.org/10.3390/ijms21249554)
15. Singh D, Singh A, Grover P, et al.: Assessment of the impact of the Hospital Anxiety and Depression Scale on the initiation of treatment in newly diagnosed cancer patients in a safety-net hospital. *J Clin Oncol*. 2017, 35:250.
16. Wheat LJ, Connolly-Stringfield PA, Baker RL, et al.: Disseminated histoplasmosis in the acquired immune deficiency syndrome. Clinical findings, diagnosis and treatment, and review of the literature. *Medicine (Baltimore)*. 1990, 69:361-74. [10.1097/00005792-199011000-00004](https://doi.org/10.1097/00005792-199011000-00004)
17. Assi MA, Sandid MS, Baddour LM, Roberts GD, Walker RC: Systemic histoplasmosis. A 15-year retrospective institutional review of 111 patients. *Medicine (Baltimore)*. 2007, 86:162-9. [10.1097/md.0b013e3180679130](https://doi.org/10.1097/md.0b013e3180679130)
18. Singh A, Tappeta K, Chellapuram N, Singh D: An interesting case of Serratia endocarditis in a patient with chronic myeloid leukemia. *Cureus*. 2022, 14:e21238. [10.7759/cureus.21238](https://doi.org/10.7759/cureus.21238)
19. Singh A, Ejaz A, Gunta PS, Jakulla RS, Singh D: Infective endocarditis as a complication of Crohn's disease on immunotherapy. *Cureus*. 2022, 14:e32847. [10.7759/cureus.32847](https://doi.org/10.7759/cureus.32847)
20. Singh A, Atallah S, Al-Shyouchk A, DaCunha M, Mizusawa M: Localized *Talaromyces marneffi* infection presenting as a tonsillar mass mimicking malignancy. *IDCases*. 2020, 21:e00824. [10.1016/j.idcr.2020.e00824](https://doi.org/10.1016/j.idcr.2020.e00824)
21. Filipovich A, McClain K, Grom A: Histiocytic disorders: recent insights into pathophysiology and practical guidelines. *Biol Blood Marrow Transplant*. 2010, 16:S82-9. [10.1016/j.bbmt.2009.11.014](https://doi.org/10.1016/j.bbmt.2009.11.014)
22. Fukaya S, Yasuda S, Hashimoto T, et al.: Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. *Rheumatology (Oxford)*. 2008, 47:1686-91.

- [10.1093/rheumatology/ken342](https://doi.org/10.1093/rheumatology/ken342)
23. Otrock ZK, Eby CS: Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. *Am J Hematol.* 2015, 90:220-4. [10.1002/ajh.23911](https://doi.org/10.1002/ajh.23911)
  24. Dhote R, Simon J, Papo T, et al.: Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. *Arthritis Rheum.* 2003, 49:633-9. [10.1002/art.11368](https://doi.org/10.1002/art.11368)
  25. Tabata R, Tabata C, Terada M, Nagai T: Hemophagocytic syndrome in elderly patients with underlying autoimmune diseases. *Clin Rheumatol.* 2009, 28:461-4. [10.1007/s10067-009-1086-2](https://doi.org/10.1007/s10067-009-1086-2)
  26. Knox B, Singh D, Mai H, Mirza K: Hodgkin's lymphoma with HLH and complete remission with brentuximab-based therapy. *BMJ Case Rep.* 2019, 12:e231629. [10.1136/bcr-2019-231629](https://doi.org/10.1136/bcr-2019-231629)
  27. Sathapatayavongs B, Batteiger BE, Wheat J, Slama TG, Wass JL: Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks. *Medicine (Baltimore).* 1983, 62:263-70. [10.1097/00005792-198309000-00001](https://doi.org/10.1097/00005792-198309000-00001)
  28. Cunha VS, Zampese MS, Aquino VR, Cestari TF, Goldani LZ: Mucocutaneous manifestations of disseminated histoplasmosis in patients with acquired immunodeficiency syndrome: particular aspects in a Latin-American population. *Clin Exp Dermatol.* 2007, 32:250-5. [10.1111/j.1365-2230.2007.02592.x](https://doi.org/10.1111/j.1365-2230.2007.02592.x)
  29. Henter JI, Samuelsson-Horne A, Aricò M, et al.: Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. *Blood.* 2002, 100:2367-73. [10.1182/blood-2002-01-0172](https://doi.org/10.1182/blood-2002-01-0172)
  30. Wheat LJ, Cloud G, Johnson PC, et al.: Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. *Antimicrob Agents Chemother.* 2001, 45:2354-7. [10.1128/AAC.45.8.2354-2357.2001](https://doi.org/10.1128/AAC.45.8.2354-2357.2001)
  31. Vergidis P, Avery RK, Wheat LJ, et al.: Histoplasmosis complicating tumor necrosis factor- $\alpha$  blocker therapy: a retrospective analysis of 98 cases. *Clin Infect Dis.* 2015, 61:409-17. [10.1093/cid/civ299](https://doi.org/10.1093/cid/civ299)